Clinical trial of 252Cf neutron brachytherapy vs. conventional radiotherapy for advanced cervical cancer

Y. Maruyama; R. Kryscio; J. R. Van Nagell; J. Yoneda; E. Donaldson; M. Hanson; J. L. Beach; J. M. Feola; A. Martin; C. Parker

doi:10.1016/0360-3016(85)90335-9

Clinical trial of ²⁵²Cf neutron brachytherapy vs. conventional radiotherapy for advanced cervical cancer

Y. Maruyama, R. Kryscio, J. R. Van Nagell, J. Yoneda, E. Donaldson, M. Hanson, J. L. Beach, J. M. Feola, A. Martin, C. Parker

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

²⁵²Cf, a neutron emitting radioactive transplutonium isotope, was tested for its efficacy against advanced bulky Stage III-IV cancers of the cervix in a clinical trial at the University of Kentucky Medical Center. Eighty-two patients were treated during 1976-1979 and followed for 5-year survival and tumor control. Three different treatment methods went on sequentially and concurrently, that is, (a) conventional whole pelvis photon with delayed ¹³⁷Cs implants, (b) conventional photon therapy with delayed ²⁵²Cf implants, and (c) ²⁵²Cf implants ("early") preceding photon therapy. There were 12% 5-year survival for Stage IIIB cancers by conventional therapy, and 15% by delayed Z5ZCf implant therapy. For early Z5ZCf implant therapy there were 54% 5-year survivals with 4% complications and 65% 5-year local control, but distant metastases became a prominent delayed failure pattern.

Original language	English
Pages (from-to)	1475-1482
Number of pages	8
Journal	International Journal of Radiation Oncology Biology Physics
Volume	11
Issue number	8
DOIs	https://doi.org/10.1016/0360-3016(85)90335-9
State	Published - Aug 1985

Keywords

5 year survival
Cf-252
Comparison efficacy
Conventional photon
Schedule
advanced cervical cancer
neutron brachytherapy

ASJC Scopus subject areas

Radiation
Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0360-3016(85)90335-9

Cite this

Maruyama, Y., Kryscio, R., Van Nagell, J. R., Yoneda, J., Donaldson, E., Hanson, M., Beach, J. L., Feola, J. M., Martin, A., & Parker, C. (1985). Clinical trial of ²⁵²Cf neutron brachytherapy vs. conventional radiotherapy for advanced cervical cancer. International Journal of Radiation Oncology Biology Physics, 11(8), 1475-1482. https://doi.org/10.1016/0360-3016(85)90335-9

@article{5631b3a0724346aab0b18d7b6dd7b022,

title = "Clinical trial of 252Cf neutron brachytherapy vs. conventional radiotherapy for advanced cervical cancer",

abstract = "252Cf, a neutron emitting radioactive transplutonium isotope, was tested for its efficacy against advanced bulky Stage III-IV cancers of the cervix in a clinical trial at the University of Kentucky Medical Center. Eighty-two patients were treated during 1976-1979 and followed for 5-year survival and tumor control. Three different treatment methods went on sequentially and concurrently, that is, (a) conventional whole pelvis photon with delayed 137Cs implants, (b) conventional photon therapy with delayed 252Cf implants, and (c) 252Cf implants ({"}early{"}) preceding photon therapy. There were 12% 5-year survival for Stage IIIB cancers by conventional therapy, and 15% by delayed Z5ZCf implant therapy. For early Z5ZCf implant therapy there were 54% 5-year survivals with 4% complications and 65% 5-year local control, but distant metastases became a prominent delayed failure pattern.",

keywords = "5 year survival, Cf-252, Comparison efficacy, Conventional photon, Schedule, advanced cervical cancer, neutron brachytherapy",

author = "Y. Maruyama and R. Kryscio and {Van Nagell}, {J. R.} and J. Yoneda and E. Donaldson and M. Hanson and Beach, {J. L.} and Feola, {J. M.} and A. Martin and C. Parker",

year = "1985",

month = aug,

doi = "10.1016/0360-3016(85)90335-9",

language = "English",

volume = "11",

pages = "1475--1482",

number = "8",

}

Maruyama, Y, Kryscio, R, Van Nagell, JR, Yoneda, J, Donaldson, E, Hanson, M, Beach, JL, Feola, JM, Martin, A & Parker, C 1985, 'Clinical trial of ²⁵²Cf neutron brachytherapy vs. conventional radiotherapy for advanced cervical cancer', International Journal of Radiation Oncology Biology Physics, vol. 11, no. 8, pp. 1475-1482. https://doi.org/10.1016/0360-3016(85)90335-9

TY - JOUR

T1 - Clinical trial of 252Cf neutron brachytherapy vs. conventional radiotherapy for advanced cervical cancer

AU - Maruyama, Y.

AU - Kryscio, R.

AU - Van Nagell, J. R.

AU - Yoneda, J.

AU - Donaldson, E.

AU - Hanson, M.

AU - Beach, J. L.

AU - Feola, J. M.

AU - Martin, A.

AU - Parker, C.

PY - 1985/8

Y1 - 1985/8

N2 - 252Cf, a neutron emitting radioactive transplutonium isotope, was tested for its efficacy against advanced bulky Stage III-IV cancers of the cervix in a clinical trial at the University of Kentucky Medical Center. Eighty-two patients were treated during 1976-1979 and followed for 5-year survival and tumor control. Three different treatment methods went on sequentially and concurrently, that is, (a) conventional whole pelvis photon with delayed 137Cs implants, (b) conventional photon therapy with delayed 252Cf implants, and (c) 252Cf implants ("early") preceding photon therapy. There were 12% 5-year survival for Stage IIIB cancers by conventional therapy, and 15% by delayed Z5ZCf implant therapy. For early Z5ZCf implant therapy there were 54% 5-year survivals with 4% complications and 65% 5-year local control, but distant metastases became a prominent delayed failure pattern.

AB - 252Cf, a neutron emitting radioactive transplutonium isotope, was tested for its efficacy against advanced bulky Stage III-IV cancers of the cervix in a clinical trial at the University of Kentucky Medical Center. Eighty-two patients were treated during 1976-1979 and followed for 5-year survival and tumor control. Three different treatment methods went on sequentially and concurrently, that is, (a) conventional whole pelvis photon with delayed 137Cs implants, (b) conventional photon therapy with delayed 252Cf implants, and (c) 252Cf implants ("early") preceding photon therapy. There were 12% 5-year survival for Stage IIIB cancers by conventional therapy, and 15% by delayed Z5ZCf implant therapy. For early Z5ZCf implant therapy there were 54% 5-year survivals with 4% complications and 65% 5-year local control, but distant metastases became a prominent delayed failure pattern.

KW - 5 year survival

KW - Cf-252

KW - Comparison efficacy

KW - Conventional photon

KW - Schedule

KW - advanced cervical cancer

KW - neutron brachytherapy

UR - http://www.scopus.com/inward/record.url?scp=0021893544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021893544&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(85)90335-9

DO - 10.1016/0360-3016(85)90335-9

M3 - Article

C2 - 4019271

AN - SCOPUS:0021893544

VL - 11

SP - 1475

EP - 1482

IS - 8

ER -